

# Global Myelofibrosis Drug Market Growth 2023-2029

<https://marketpublishers.com/r/G801E12D73F2EN.html>

Date: March 2023

Pages: 94

Price: US\$ 3,660.00 (Single User License)

ID: G801E12D73F2EN

## Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

The global Myelofibrosis Drug market size is projected to grow from US\$ million in 2022 to US\$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Myelofibrosis Drug is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Myelofibrosis Drug is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Myelofibrosis Drug is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Myelofibrosis Drug players cover GSK, AbbVie, Novartis, Celgene, Grunenthal, Incyte, CTI BioPharma, Bristol Myers Squibb and Suzhou Zelgen Biopharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

Myelofibrosis is an uncommon type of bone marrow cancer that disrupts your body's normal production of blood cells. Myelofibrosis causes extensive scarring in your bone marrow, leading to severe anemia that can cause weakness and fatigue.

LPI (LP Information)' newest research report, the "Myelofibrosis Drug Industry Forecast" looks at past sales and reviews total world Myelofibrosis Drug sales in 2022, providing a comprehensive analysis by region and market sector of projected Myelofibrosis Drug sales for 2023 through 2029. With Myelofibrosis Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in

US\$ millions of the world Myelofibrosis Drug industry.

This Insight Report provides a comprehensive analysis of the global Myelofibrosis Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Myelofibrosis Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Myelofibrosis Drug market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Myelofibrosis Drug and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Myelofibrosis Drug.

This report presents a comprehensive overview, market shares, and growth opportunities of Myelofibrosis Drug market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type

JAK 1

JAK 2

Others

Segmentation by application

Primary Myelofibrosis

Secondary Myelofibrosis

This report also splits the market by region:

### Americas

United States

Canada

Mexico

Brazil

### APAC

China

Japan

Korea

Southeast Asia

India

Australia

### Europe

Germany

France

UK

Italy

Russia

### Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

GSK

AbbVie

Novartis

Celgene

Grünenthal

Incyte

CTI BioPharma

Bristol Myers Squibb

Suzhou Zelgen Biopharmaceuticals

Key Questions Addressed in this Report

What is the 10-year outlook for the global Myelofibrosis Drug market?

What factors are driving Myelofibrosis Drug market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Myelofibrosis Drug market opportunities vary by end market size?

How does Myelofibrosis Drug break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

## Contents

### 1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

### 2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
  - 2.1.1 Global Myelofibrosis Drug Annual Sales 2018-2029
  - 2.1.2 World Current & Future Analysis for Myelofibrosis Drug by Geographic Region, 2018, 2022 & 2029
  - 2.1.3 World Current & Future Analysis for Myelofibrosis Drug by Country/Region, 2018, 2022 & 2029
- 2.2 Myelofibrosis Drug Segment by Type
  - 2.2.1 JAK
  - 2.2.2 JAK
  - 2.2.3 Others
- 2.3 Myelofibrosis Drug Sales by Type
  - 2.3.1 Global Myelofibrosis Drug Sales Market Share by Type (2018-2023)
  - 2.3.2 Global Myelofibrosis Drug Revenue and Market Share by Type (2018-2023)
  - 2.3.3 Global Myelofibrosis Drug Sale Price by Type (2018-2023)
- 2.4 Myelofibrosis Drug Segment by Application
  - 2.4.1 Primary Myelofibrosis
  - 2.4.2 Secondary Myelofibrosis
- 2.5 Myelofibrosis Drug Sales by Application
  - 2.5.1 Global Myelofibrosis Drug Sale Market Share by Application (2018-2023)
  - 2.5.2 Global Myelofibrosis Drug Revenue and Market Share by Application (2018-2023)
  - 2.5.3 Global Myelofibrosis Drug Sale Price by Application (2018-2023)

### 3 GLOBAL MYELOFIBROSIS DRUG BY COMPANY

- 3.1 Global Myelofibrosis Drug Breakdown Data by Company
  - 3.1.1 Global Myelofibrosis Drug Annual Sales by Company (2018-2023)
  - 3.1.2 Global Myelofibrosis Drug Sales Market Share by Company (2018-2023)
- 3.2 Global Myelofibrosis Drug Annual Revenue by Company (2018-2023)
  - 3.2.1 Global Myelofibrosis Drug Revenue by Company (2018-2023)
  - 3.2.2 Global Myelofibrosis Drug Revenue Market Share by Company (2018-2023)
- 3.3 Global Myelofibrosis Drug Sale Price by Company
- 3.4 Key Manufacturers Myelofibrosis Drug Producing Area Distribution, Sales Area, Product Type
  - 3.4.1 Key Manufacturers Myelofibrosis Drug Product Location Distribution
  - 3.4.2 Players Myelofibrosis Drug Products Offered
- 3.5 Market Concentration Rate Analysis
  - 3.5.1 Competition Landscape Analysis
  - 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
- 3.6 New Products and Potential Entrants
- 3.7 Mergers & Acquisitions, Expansion

## **4 WORLD HISTORIC REVIEW FOR MYELOFIBROSIS DRUG BY GEOGRAPHIC REGION**

- 4.1 World Historic Myelofibrosis Drug Market Size by Geographic Region (2018-2023)
  - 4.1.1 Global Myelofibrosis Drug Annual Sales by Geographic Region (2018-2023)
  - 4.1.2 Global Myelofibrosis Drug Annual Revenue by Geographic Region (2018-2023)
- 4.2 World Historic Myelofibrosis Drug Market Size by Country/Region (2018-2023)
  - 4.2.1 Global Myelofibrosis Drug Annual Sales by Country/Region (2018-2023)
  - 4.2.2 Global Myelofibrosis Drug Annual Revenue by Country/Region (2018-2023)
- 4.3 Americas Myelofibrosis Drug Sales Growth
- 4.4 APAC Myelofibrosis Drug Sales Growth
- 4.5 Europe Myelofibrosis Drug Sales Growth
- 4.6 Middle East & Africa Myelofibrosis Drug Sales Growth

## **5 AMERICAS**

- 5.1 Americas Myelofibrosis Drug Sales by Country
  - 5.1.1 Americas Myelofibrosis Drug Sales by Country (2018-2023)
  - 5.1.2 Americas Myelofibrosis Drug Revenue by Country (2018-2023)
- 5.2 Americas Myelofibrosis Drug Sales by Type
- 5.3 Americas Myelofibrosis Drug Sales by Application

- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil

## **6 APAC**

- 6.1 APAC Myelofibrosis Drug Sales by Region
  - 6.1.1 APAC Myelofibrosis Drug Sales by Region (2018-2023)
  - 6.1.2 APAC Myelofibrosis Drug Revenue by Region (2018-2023)
- 6.2 APAC Myelofibrosis Drug Sales by Type
- 6.3 APAC Myelofibrosis Drug Sales by Application
- 6.4 China
- 6.5 Japan
- 6.6 South Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 6.10 China Taiwan

## **7 EUROPE**

- 7.1 Europe Myelofibrosis Drug by Country
  - 7.1.1 Europe Myelofibrosis Drug Sales by Country (2018-2023)
  - 7.1.2 Europe Myelofibrosis Drug Revenue by Country (2018-2023)
- 7.2 Europe Myelofibrosis Drug Sales by Type
- 7.3 Europe Myelofibrosis Drug Sales by Application
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia

## **8 MIDDLE EAST & AFRICA**

- 8.1 Middle East & Africa Myelofibrosis Drug by Country
  - 8.1.1 Middle East & Africa Myelofibrosis Drug Sales by Country (2018-2023)
  - 8.1.2 Middle East & Africa Myelofibrosis Drug Revenue by Country (2018-2023)
- 8.2 Middle East & Africa Myelofibrosis Drug Sales by Type



8.3 Middle East & Africa Myelofibrosis Drug Sales by Application

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

## **9 MARKET DRIVERS, CHALLENGES AND TRENDS**

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

## **10 MANUFACTURING COST STRUCTURE ANALYSIS**

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Myelofibrosis Drug

10.3 Manufacturing Process Analysis of Myelofibrosis Drug

10.4 Industry Chain Structure of Myelofibrosis Drug

## **11 MARKETING, DISTRIBUTORS AND CUSTOMER**

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Myelofibrosis Drug Distributors

11.3 Myelofibrosis Drug Customer

## **12 WORLD FORECAST REVIEW FOR MYELOFIBROSIS DRUG BY GEOGRAPHIC REGION**

12.1 Global Myelofibrosis Drug Market Size Forecast by Region

12.1.1 Global Myelofibrosis Drug Forecast by Region (2024-2029)

12.1.2 Global Myelofibrosis Drug Annual Revenue Forecast by Region (2024-2029)

12.2 Americas Forecast by Country

12.3 APAC Forecast by Region

12.4 Europe Forecast by Country

12.5 Middle East & Africa Forecast by Country

12.6 Global Myelofibrosis Drug Forecast by Type

## 12.7 Global Myelofibrosis Drug Forecast by Application

### **13 KEY PLAYERS ANALYSIS**

#### 13.1 GSK

13.1.1 GSK Company Information

13.1.2 GSK Myelofibrosis Drug Product Portfolios and Specifications

13.1.3 GSK Myelofibrosis Drug Sales, Revenue, Price and Gross Margin (2018-2023)

13.1.4 GSK Main Business Overview

13.1.5 GSK Latest Developments

#### 13.2 AbbVie

13.2.1 AbbVie Company Information

13.2.2 AbbVie Myelofibrosis Drug Product Portfolios and Specifications

13.2.3 AbbVie Myelofibrosis Drug Sales, Revenue, Price and Gross Margin  
(2018-2023)

13.2.4 AbbVie Main Business Overview

13.2.5 AbbVie Latest Developments

#### 13.3 Novartis

13.3.1 Novartis Company Information

13.3.2 Novartis Myelofibrosis Drug Product Portfolios and Specifications

13.3.3 Novartis Myelofibrosis Drug Sales, Revenue, Price and Gross Margin  
(2018-2023)

13.3.4 Novartis Main Business Overview

13.3.5 Novartis Latest Developments

#### 13.4 Celgene

13.4.1 Celgene Company Information

13.4.2 Celgene Myelofibrosis Drug Product Portfolios and Specifications

13.4.3 Celgene Myelofibrosis Drug Sales, Revenue, Price and Gross Margin  
(2018-2023)

13.4.4 Celgene Main Business Overview

13.4.5 Celgene Latest Developments

#### 13.5 Grunenthal

13.5.1 Grunenthal Company Information

13.5.2 Grunenthal Myelofibrosis Drug Product Portfolios and Specifications

13.5.3 Grunenthal Myelofibrosis Drug Sales, Revenue, Price and Gross Margin  
(2018-2023)

13.5.4 Grunenthal Main Business Overview

13.5.5 Grunenthal Latest Developments

#### 13.6 Incyte

- 13.6.1 Incyte Company Information
- 13.6.2 Incyte Myelofibrosis Drug Product Portfolios and Specifications
- 13.6.3 Incyte Myelofibrosis Drug Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.6.4 Incyte Main Business Overview
- 13.6.5 Incyte Latest Developments
- 13.7 CTI BioPharma
  - 13.7.1 CTI BioPharma Company Information
  - 13.7.2 CTI BioPharma Myelofibrosis Drug Product Portfolios and Specifications
  - 13.7.3 CTI BioPharma Myelofibrosis Drug Sales, Revenue, Price and Gross Margin (2018-2023)
  - 13.7.4 CTI BioPharma Main Business Overview
  - 13.7.5 CTI BioPharma Latest Developments
- 13.8 Bristol Myers Squibb
  - 13.8.1 Bristol Myers Squibb Company Information
  - 13.8.2 Bristol Myers Squibb Myelofibrosis Drug Product Portfolios and Specifications
  - 13.8.3 Bristol Myers Squibb Myelofibrosis Drug Sales, Revenue, Price and Gross Margin (2018-2023)
  - 13.8.4 Bristol Myers Squibb Main Business Overview
  - 13.8.5 Bristol Myers Squibb Latest Developments
- 13.9 Suzhou Zelgen Biopharmaceuticals
  - 13.9.1 Suzhou Zelgen Biopharmaceuticals Company Information
  - 13.9.2 Suzhou Zelgen Biopharmaceuticals Myelofibrosis Drug Product Portfolios and Specifications
  - 13.9.3 Suzhou Zelgen Biopharmaceuticals Myelofibrosis Drug Sales, Revenue, Price and Gross Margin (2018-2023)
  - 13.9.4 Suzhou Zelgen Biopharmaceuticals Main Business Overview
  - 13.9.5 Suzhou Zelgen Biopharmaceuticals Latest Developments

## **14 RESEARCH FINDINGS AND CONCLUSION**

## List Of Tables

### LIST OF TABLES

- Table 1. Myelofibrosis Drug Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & (\$ millions)
- Table 2. Myelofibrosis Drug Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & (\$ millions)
- Table 3. Major Players of JAK 1
- Table 4. Major Players of JAK 2
- Table 5. Major Players of Others
- Table 6. Global Myelofibrosis Drug Sales by Type (2018-2023) & (K Units)
- Table 7. Global Myelofibrosis Drug Sales Market Share by Type (2018-2023)
- Table 8. Global Myelofibrosis Drug Revenue by Type (2018-2023) & (\$ million)
- Table 9. Global Myelofibrosis Drug Revenue Market Share by Type (2018-2023)
- Table 10. Global Myelofibrosis Drug Sale Price by Type (2018-2023) & (US\$/Unit)
- Table 11. Global Myelofibrosis Drug Sales by Application (2018-2023) & (K Units)
- Table 12. Global Myelofibrosis Drug Sales Market Share by Application (2018-2023)
- Table 13. Global Myelofibrosis Drug Revenue by Application (2018-2023)
- Table 14. Global Myelofibrosis Drug Revenue Market Share by Application (2018-2023)
- Table 15. Global Myelofibrosis Drug Sale Price by Application (2018-2023) & (US\$/Unit)
- Table 16. Global Myelofibrosis Drug Sales by Company (2018-2023) & (K Units)
- Table 17. Global Myelofibrosis Drug Sales Market Share by Company (2018-2023)
- Table 18. Global Myelofibrosis Drug Revenue by Company (2018-2023) (\$ Millions)
- Table 19. Global Myelofibrosis Drug Revenue Market Share by Company (2018-2023)
- Table 20. Global Myelofibrosis Drug Sale Price by Company (2018-2023) & (US\$/Unit)
- Table 21. Key Manufacturers Myelofibrosis Drug Producing Area Distribution and Sales Area
- Table 22. Players Myelofibrosis Drug Products Offered
- Table 23. Myelofibrosis Drug Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
- Table 24. New Products and Potential Entrants
- Table 25. Mergers & Acquisitions, Expansion
- Table 26. Global Myelofibrosis Drug Sales by Geographic Region (2018-2023) & (K Units)
- Table 27. Global Myelofibrosis Drug Sales Market Share Geographic Region (2018-2023)
- Table 28. Global Myelofibrosis Drug Revenue by Geographic Region (2018-2023) & (\$ millions)
- Table 29. Global Myelofibrosis Drug Revenue Market Share by Geographic Region

(2018-2023)

Table 30. Global Myelofibrosis Drug Sales by Country/Region (2018-2023) & (K Units)

Table 31. Global Myelofibrosis Drug Sales Market Share by Country/Region  
(2018-2023)

Table 32. Global Myelofibrosis Drug Revenue by Country/Region (2018-2023) & (\$  
millions)

Table 33. Global Myelofibrosis Drug Revenue Market Share by Country/Region  
(2018-2023)

Table 34. Americas Myelofibrosis Drug Sales by Country (2018-2023) & (K Units)

Table 35. Americas Myelofibrosis Drug Sales Market Share by Country (2018-2023)

Table 36. Americas Myelofibrosis Drug Revenue by Country (2018-2023) & (\$ Millions)

Table 37. Americas Myelofibrosis Drug Revenue Market Share by Country (2018-2023)

Table 38. Americas Myelofibrosis Drug Sales by Type (2018-2023) & (K Units)

Table 39. Americas Myelofibrosis Drug Sales by Application (2018-2023) & (K Units)

Table 40. APAC Myelofibrosis Drug Sales by Region (2018-2023) & (K Units)

Table 41. APAC Myelofibrosis Drug Sales Market Share by Region (2018-2023)

Table 42. APAC Myelofibrosis Drug Revenue by Region (2018-2023) & (\$ Millions)

Table 43. APAC Myelofibrosis Drug Revenue Market Share by Region (2018-2023)

Table 44. APAC Myelofibrosis Drug Sales by Type (2018-2023) & (K Units)

Table 45. APAC Myelofibrosis Drug Sales by Application (2018-2023) & (K Units)

Table 46. Europe Myelofibrosis Drug Sales by Country (2018-2023) & (K Units)

Table 47. Europe Myelofibrosis Drug Sales Market Share by Country (2018-2023)

Table 48. Europe Myelofibrosis Drug Revenue by Country (2018-2023) & (\$ Millions)

Table 49. Europe Myelofibrosis Drug Revenue Market Share by Country (2018-2023)

Table 50. Europe Myelofibrosis Drug Sales by Type (2018-2023) & (K Units)

Table 51. Europe Myelofibrosis Drug Sales by Application (2018-2023) & (K Units)

Table 52. Middle East & Africa Myelofibrosis Drug Sales by Country (2018-2023) & (K  
Units)

Table 53. Middle East & Africa Myelofibrosis Drug Sales Market Share by Country  
(2018-2023)

Table 54. Middle East & Africa Myelofibrosis Drug Revenue by Country (2018-2023) &  
(\$ Millions)

Table 55. Middle East & Africa Myelofibrosis Drug Revenue Market Share by Country  
(2018-2023)

Table 56. Middle East & Africa Myelofibrosis Drug Sales by Type (2018-2023) & (K  
Units)

Table 57. Middle East & Africa Myelofibrosis Drug Sales by Application (2018-2023) &  
(K Units)

Table 58. Key Market Drivers & Growth Opportunities of Myelofibrosis Drug

- Table 59. Key Market Challenges & Risks of Myelofibrosis Drug
- Table 60. Key Industry Trends of Myelofibrosis Drug
- Table 61. Myelofibrosis Drug Raw Material
- Table 62. Key Suppliers of Raw Materials
- Table 63. Myelofibrosis Drug Distributors List
- Table 64. Myelofibrosis Drug Customer List
- Table 65. Global Myelofibrosis Drug Sales Forecast by Region (2024-2029) & (K Units)
- Table 66. Global Myelofibrosis Drug Revenue Forecast by Region (2024-2029) & (\$ millions)
- Table 67. Americas Myelofibrosis Drug Sales Forecast by Country (2024-2029) & (K Units)
- Table 68. Americas Myelofibrosis Drug Revenue Forecast by Country (2024-2029) & (\$ millions)
- Table 69. APAC Myelofibrosis Drug Sales Forecast by Region (2024-2029) & (K Units)
- Table 70. APAC Myelofibrosis Drug Revenue Forecast by Region (2024-2029) & (\$ millions)
- Table 71. Europe Myelofibrosis Drug Sales Forecast by Country (2024-2029) & (K Units)
- Table 72. Europe Myelofibrosis Drug Revenue Forecast by Country (2024-2029) & (\$ millions)
- Table 73. Middle East & Africa Myelofibrosis Drug Sales Forecast by Country (2024-2029) & (K Units)
- Table 74. Middle East & Africa Myelofibrosis Drug Revenue Forecast by Country (2024-2029) & (\$ millions)
- Table 75. Global Myelofibrosis Drug Sales Forecast by Type (2024-2029) & (K Units)
- Table 76. Global Myelofibrosis Drug Revenue Forecast by Type (2024-2029) & (\$ Millions)
- Table 77. Global Myelofibrosis Drug Sales Forecast by Application (2024-2029) & (K Units)
- Table 78. Global Myelofibrosis Drug Revenue Forecast by Application (2024-2029) & (\$ Millions)
- Table 79. GSK Basic Information, Myelofibrosis Drug Manufacturing Base, Sales Area and Its Competitors
- Table 80. GSK Myelofibrosis Drug Product Portfolios and Specifications
- Table 81. GSK Myelofibrosis Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)
- Table 82. GSK Main Business
- Table 83. GSK Latest Developments
- Table 84. AbbVie Basic Information, Myelofibrosis Drug Manufacturing Base, Sales

## Area and Its Competitors

Table 85. AbbVie Myelofibrosis Drug Product Portfolios and Specifications

Table 86. AbbVie Myelofibrosis Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 87. AbbVie Main Business

Table 88. AbbVie Latest Developments

Table 89. Novartis Basic Information, Myelofibrosis Drug Manufacturing Base, Sales Area and Its Competitors

Table 90. Novartis Myelofibrosis Drug Product Portfolios and Specifications

Table 91. Novartis Myelofibrosis Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 92. Novartis Main Business

Table 93. Novartis Latest Developments

Table 94. Celgene Basic Information, Myelofibrosis Drug Manufacturing Base, Sales Area and Its Competitors

Table 95. Celgene Myelofibrosis Drug Product Portfolios and Specifications

Table 96. Celgene Myelofibrosis Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 97. Celgene Main Business

Table 98. Celgene Latest Developments

Table 99. Grunenthal Basic Information, Myelofibrosis Drug Manufacturing Base, Sales Area and Its Competitors

Table 100. Grunenthal Myelofibrosis Drug Product Portfolios and Specifications

Table 101. Grunenthal Myelofibrosis Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 102. Grunenthal Main Business

Table 103. Grunenthal Latest Developments

Table 104. Incyte Basic Information, Myelofibrosis Drug Manufacturing Base, Sales Area and Its Competitors

Table 105. Incyte Myelofibrosis Drug Product Portfolios and Specifications

Table 106. Incyte Myelofibrosis Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 107. Incyte Main Business

Table 108. Incyte Latest Developments

Table 109. CTI BioPharma Basic Information, Myelofibrosis Drug Manufacturing Base, Sales Area and Its Competitors

Table 110. CTI BioPharma Myelofibrosis Drug Product Portfolios and Specifications

Table 111. CTI BioPharma Myelofibrosis Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 112. CTI BioPharma Main Business

Table 113. CTI BioPharma Latest Developments

Table 114. Bristol Myers Squibb Basic Information, Myelofibrosis Drug Manufacturing Base, Sales Area and Its Competitors

Table 115. Bristol Myers Squibb Myelofibrosis Drug Product Portfolios and Specifications

Table 116. Bristol Myers Squibb Myelofibrosis Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 117. Bristol Myers Squibb Main Business

Table 118. Bristol Myers Squibb Latest Developments

Table 119. Suzhou Zelgen Biopharmaceuticals Basic Information, Myelofibrosis Drug Manufacturing Base, Sales Area and Its Competitors

Table 120. Suzhou Zelgen Biopharmaceuticals Myelofibrosis Drug Product Portfolios and Specifications

Table 121. Suzhou Zelgen Biopharmaceuticals Myelofibrosis Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 122. Suzhou Zelgen Biopharmaceuticals Main Business

Table 123. Suzhou Zelgen Biopharmaceuticals Latest Developments



## List Of Figures

### LIST OF FIGURES

- Figure 1. Picture of Myelofibrosis Drug
- Figure 2. Myelofibrosis Drug Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Myelofibrosis Drug Sales Growth Rate 2018-2029 (K Units)
- Figure 7. Global Myelofibrosis Drug Revenue Growth Rate 2018-2029 (\$ Millions)
- Figure 8. Myelofibrosis Drug Sales by Region (2018, 2022 & 2029) & (\$ Millions)
- Figure 9. Product Picture of JAK 1
- Figure 10. Product Picture of JAK 2
- Figure 11. Product Picture of Others
- Figure 12. Global Myelofibrosis Drug Sales Market Share by Type in 2022
- Figure 13. Global Myelofibrosis Drug Revenue Market Share by Type (2018-2023)
- Figure 14. Myelofibrosis Drug Consumed in Primary Myelofibrosis
- Figure 15. Global Myelofibrosis Drug Market: Primary Myelofibrosis (2018-2023) & (K Units)
- Figure 16. Myelofibrosis Drug Consumed in Secondary Myelofibrosis
- Figure 17. Global Myelofibrosis Drug Market: Secondary Myelofibrosis (2018-2023) & (K Units)
- Figure 18. Global Myelofibrosis Drug Sales Market Share by Application (2022)
- Figure 19. Global Myelofibrosis Drug Revenue Market Share by Application in 2022
- Figure 20. Myelofibrosis Drug Sales Market by Company in 2022 (K Units)
- Figure 21. Global Myelofibrosis Drug Sales Market Share by Company in 2022
- Figure 22. Myelofibrosis Drug Revenue Market by Company in 2022 (\$ Million)
- Figure 23. Global Myelofibrosis Drug Revenue Market Share by Company in 2022
- Figure 24. Global Myelofibrosis Drug Sales Market Share by Geographic Region (2018-2023)
- Figure 25. Global Myelofibrosis Drug Revenue Market Share by Geographic Region in 2022
- Figure 26. Americas Myelofibrosis Drug Sales 2018-2023 (K Units)
- Figure 27. Americas Myelofibrosis Drug Revenue 2018-2023 (\$ Millions)
- Figure 28. APAC Myelofibrosis Drug Sales 2018-2023 (K Units)
- Figure 29. APAC Myelofibrosis Drug Revenue 2018-2023 (\$ Millions)
- Figure 30. Europe Myelofibrosis Drug Sales 2018-2023 (K Units)
- Figure 31. Europe Myelofibrosis Drug Revenue 2018-2023 (\$ Millions)

- Figure 32. Middle East & Africa Myelofibrosis Drug Sales 2018-2023 (K Units)
- Figure 33. Middle East & Africa Myelofibrosis Drug Revenue 2018-2023 (\$ Millions)
- Figure 34. Americas Myelofibrosis Drug Sales Market Share by Country in 2022
- Figure 35. Americas Myelofibrosis Drug Revenue Market Share by Country in 2022
- Figure 36. Americas Myelofibrosis Drug Sales Market Share by Type (2018-2023)
- Figure 37. Americas Myelofibrosis Drug Sales Market Share by Application (2018-2023)
- Figure 38. United States Myelofibrosis Drug Revenue Growth 2018-2023 (\$ Millions)
- Figure 39. Canada Myelofibrosis Drug Revenue Growth 2018-2023 (\$ Millions)
- Figure 40. Mexico Myelofibrosis Drug Revenue Growth 2018-2023 (\$ Millions)
- Figure 41. Brazil Myelofibrosis Drug Revenue Growth 2018-2023 (\$ Millions)
- Figure 42. APAC Myelofibrosis Drug Sales Market Share by Region in 2022
- Figure 43. APAC Myelofibrosis Drug Revenue Market Share by Regions in 2022
- Figure 44. APAC Myelofibrosis Drug Sales Market Share by Type (2018-2023)
- Figure 45. APAC Myelofibrosis Drug Sales Market Share by Application (2018-2023)
- Figure 46. China Myelofibrosis Drug Revenue Growth 2018-2023 (\$ Millions)
- Figure 47. Japan Myelofibrosis Drug Revenue Growth 2018-2023 (\$ Millions)
- Figure 48. South Korea Myelofibrosis Drug Revenue Growth 2018-2023 (\$ Millions)
- Figure 49. Southeast Asia Myelofibrosis Drug Revenue Growth 2018-2023 (\$ Millions)
- Figure 50. India Myelofibrosis Drug Revenue Growth 2018-2023 (\$ Millions)
- Figure 51. Australia Myelofibrosis Drug Revenue Growth 2018-2023 (\$ Millions)
- Figure 52. China Taiwan Myelofibrosis Drug Revenue Growth 2018-2023 (\$ Millions)
- Figure 53. Europe Myelofibrosis Drug Sales Market Share by Country in 2022
- Figure 54. Europe Myelofibrosis Drug Revenue Market Share by Country in 2022
- Figure 55. Europe Myelofibrosis Drug Sales Market Share by Type (2018-2023)
- Figure 56. Europe Myelofibrosis Drug Sales Market Share by Application (2018-2023)
- Figure 57. Germany Myelofibrosis Drug Revenue Growth 2018-2023 (\$ Millions)
- Figure 58. France Myelofibrosis Drug Revenue Growth 2018-2023 (\$ Millions)
- Figure 59. UK Myelofibrosis Drug Revenue Growth 2018-2023 (\$ Millions)
- Figure 60. Italy Myelofibrosis Drug Revenue Growth 2018-2023 (\$ Millions)
- Figure 61. Russia Myelofibrosis Drug Revenue Growth 2018-2023 (\$ Millions)
- Figure 62. Middle East & Africa Myelofibrosis Drug Sales Market Share by Country in 2022
- Figure 63. Middle East & Africa Myelofibrosis Drug Revenue Market Share by Country in 2022
- Figure 64. Middle East & Africa Myelofibrosis Drug Sales Market Share by Type (2018-2023)
- Figure 65. Middle East & Africa Myelofibrosis Drug Sales Market Share by Application (2018-2023)
- Figure 66. Egypt Myelofibrosis Drug Revenue Growth 2018-2023 (\$ Millions)

Figure 67. South Africa Myelofibrosis Drug Revenue Growth 2018-2023 (\$ Millions)

Figure 68. Israel Myelofibrosis Drug Revenue Growth 2018-2023 (\$ Millions)

Figure 69. Turkey Myelofibrosis Drug Revenue Growth 2018-2023 (\$ Millions)

Figure 70. GCC Country Myelofibrosis Drug Revenue Growth 2018-2023 (\$ Millions)

Figure 71. Manufacturing Cost Structure Analysis of Myelofibrosis Drug in 2022

Figure 72. Manufacturing Process Analysis of Myelofibrosis Drug

Figure 73. Industry Chain Structure of Myelofibrosis Drug

Figure 74. Channels of Distribution

Figure 75. Global Myelofibrosis Drug Sales Market Forecast by Region (2024-2029)

Figure 76. Global Myelofibrosis Drug Revenue Market Share Forecast by Region (2024-2029)

Figure 77. Global Myelofibrosis Drug Sales Market Share Forecast by Type (2024-2029)

Figure 78. Global Myelofibrosis Drug Revenue Market Share Forecast by Type (2024-2029)

Figure 79. Global Myelofibrosis Drug Sales Market Share Forecast by Application (2024-2029)

Figure 80. Global Myelofibrosis Drug Revenue Market Share Forecast by Application (2024-2029)

## I would like to order

Product name: Global Myelofibrosis Drug Market Growth 2023-2029

Product link: <https://marketpublishers.com/r/G801E12D73F2EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G801E12D73F2EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970